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Fundamental roles for hypoxia signalling in adipose tissue metabolism and inflammation 
in obesity  
Zoi Michailidou, PhD 
Centre for Cardiovascular Sciences, University of Edinburgh 
 
Abstract 
 
Over a decade ago the notion that adipose tissue could become hypoxic during adipose 
expansion with obesity was proposed.  A series of elegant studies in mouse models of obesity 
have demonstrated that severe adiposity could lead to low oxygen levels within adipose tissue, 
triggering induction of the hypoxia inducible factor (HIF) signalling cascade, and consequently 
an up-regulation of pro-inflammatory responses that lead to insulin resistance. However, 
genetic models targeting different components of the HIF pathway have produced conflicting 
results and revealing that distinct HIF isoforms play tissue-specific roles in metabolic function. 
This review discusses the consequences and mechanisms of altered oxygenation on adipocyte 
function and the potential for therapeutic targeting of HIF signalling in obesity and its 
metabolic complications.    
 
Introduction  
Hypoxia, or low oxygenation, is a feature of normal tissues in health and a pathogenic 
consequence of disease. Hypoxia triggers a plethora of cellular responses to restore 
oxygenation, normal metabolism and cell survival. The master regulators of this adaptive 
response are the hypoxia-inducible factors (HIFs) (1). Exquisite regulation of HIFs is tightly 
regulated by the cellular oxygen sensors, HIF-prolyl hydroxylases (PHDs) (2). PHDs 
hydroxylate HIFs, tagging them for recognition by the Von Hippel Lindau (VHL) ubiquitin 
ligase system and thus facilitating HIF proteasomal degradation in an oxygen-dependent 
manner (2). HIFs and PHDs are implicated in physiological processes and this is dysregulated 
in pathological conditions (1-2). Their role in regulating adipocyte function has been 
demonstrated in transgenic models targeting the HIF signalling system either systemically 
(whole animal gene knockout) or specifically in adipose tissue.    
Adipose tissue expansion in obesity can lead to local hypoxia and induction of HIF-a (3).  
Activation of the HIF-a-signalling cascade has been implicated in adipocyte dysfunction, 
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increased adipose tissue inflammation and insulin resistance in mouse models of diet-induced 
obesity (DIO) (3-7). Tissue oxygen tension is maintained by the balance between oxygen 
demand and supply. Most studies attributed the adipocyte hypoxia to reduced oxygen supply 
due to defective vascularization during expansion (3-7). Recently, however, increased oxygen 
demand has been implicated as a cause of adipocyte hypoxia (8). Thus, during high fat feeding, 
saturated fatty acids may drive stimulation of adenine nucleotide translocase 2 (ANT2), that in 
turn increases uncoupled mitochondrial respiration and thus increases oxygen consumption (8-
9).  In either case, it is evident that the excessive expansion of adipose tissue in obesity disturbs 
the balance between oxygen supply and demand.  
Although the HIF/PHD pathway has been implicated in regulating metabolic pathways in other 
key metabolic organs such as  liver and muscle that  are affected by obesity, this review focuses 
on our current understanding of the hypoxia response principally on  adipocyte function, and 
the therapeutic potential of modulating the PHD/HIF axis in obesity. 
  
The role of HIFs in obesity and related metabolic complications: HIF-1a or HIF-2a?  
Activation of adipose-HIF1a could have adverse or beneficial metabolic outcomes. The first 
study used a transgenic model of adipose overexpression of a constitutively active form of HIF-
1a and showed that this led to increased fat mass and adipocyte dysfunction with inflammation, 
fibrosis and insulin resistance in DIO (6).  This study also showed that HIF-1a activation did 
not induce the classical Vegfa-vascularisation response (6), which was also confirmed by other 
studies (10-12), rather HIF-1a induced a collagen-driven profibrotic response that led to 
maladaptive adipose tissue remodelling and insulin resistance (6).  Follow-on studies looking 
at HIF-1a deficiency strategies (using the ap2 [fabp4] promoter driven cre to produce adipose 
knock-down of ‘floxed’ gene targets) showed conflicting effects. Zhang et al. showed that 
dominant negative human HIF-1α (also under the ap2 promoter) led to susceptible to DIO 
mainly due to loss of thermogenic capacity in brown adipose tissue (BAT) (11). In contrast a 
series of studies of adipose HIF-1a deletions showed protection from DIO (8, 13,14) due to 
reduced fat mass, adipocyte size and inflammation and increased adipose mitochondrial 
biogenesis, increased energy expenditure, with improved glucose tolerance and insulin 
sensitivity. Most of the effects were apparent in white adipose tissue (WAT) with less obvious 
phenotypes in brown adipose (BAT).  
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It is becoming increasingly apparent that HIF-1a and HIF-2a have divergent roles in 
physiology and pathology in various diseases (15). It is also evident that this is the case in 
adipose function as deletion of adipose HIF-1a reverses the obesity-driven WAT 
inflammation, reduces body fat mass and protects from insulin resistance, whereas deletion of 
adipose HIF-2a, or HIF-2a heterozygosity, leads to WAT inflammation, higher WAT mass in 
DIO and insulin resistance (8,16,17). HIF-2a also seems to be more important in BAT function 
than HIF-1a, as it is one of the most highly induced genes after cold exposure (18). Consistent 
with an important biological role, loss of HIF-2α signalling impaired thermogenesis by 
decreasing Ucp1 and Vegfa expression and vascularization in BAT which was rescued by 
VEGF administration (17). Finally, adipocyte deletion of HIF-1a and HIF-2a shifted the 
phenotype towards that seen with HIF-1a deletion alone (8). Notably, HIF-1a and HIF-2a 
depletion in adipocytes was achieved by using the Fabp4-Cre mice. This approach may lead to 
recombination (gene deletion) in other cells and tissues, such as macrophages or endothelial 
cells, therefore adipocyte-specificity for the phenotypes of these models cannot be guaranteed.  
 
Nevertheless, results from a number of studies support adipocyte HIF-2a as the major driver 
of the key protective metabolic effects during adipose expansion, i.e. enhanced vascularization 
potential.  Thus, adipose-HIF-1a modulation (deletion or overexpression models) failed to 
show an effect of the most well studied HIF-a target gene, Vegfa. One possibility could be that 
targeting primarily adipocyte HIF-1a is not sufficient to induce a vascularization 
programme. Indeed, other cell types were implicated in this response, for example, in a model 
of diet-induced obesity, mice lacking myeloid HIF-1α developed a normal vasculature despite 
reduced whole adipose Vegfa levels (19). The authors concluded that myeloid HIF-1a could 
differentially regulate Vegfa levels in different cell types in adipose tissues (macrophages, 
endothelial cells and preadipocytes). Macrophage HIF-1α was highlighted as a key driver of 
pathological adipose tissue expansion. Alternatively, in the vascularization process HIF-a 
isoforms have distinct roles, HIF-1a regulates mainly endothelial cell proliferation, migration 
and sprouting, whereas HIF-2a controls vascular morphogenesis (20).  As suggested from the 
studies above (12, 17), the isoform specificity might be the key, with adipocyte HIF-2a the 
dominant isoform to drive neovascularization in adipose tissue.  
 
These studies highlight that HIF-isoforms play distinct, non-redundant roles in adipocyte 
function. HIF-2a in adipocytes is necessary to protect from adipocyte dysfunction in obesity 
and this could be due to induction of an adipocyte vascularization phenotype. The clear 
message is that careful targeting of specific HIF-a isoforms will need to be considered within 
the context of existing therapeutic regimes where adipose tissue function may impact health 
and for potential HIF targeting for obesity and diabetes therapeutics.  
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Is there adipose hypoxia in humans?  
Studies in humans have been less conclusive in demonstrating that hypoxia and HIF-a are 
directly linked to the metabolic dysfunction in obese individuals. There is a consensus that 
arterial blood oxygenation is lower in obese compared to lean individuals (21-22). Kabon et al. 
and Pasarica et al. reported that in obese the subcutaneous upper arm or abdominal WAT partial 
oxygen pressure to be significantly lower than lean individuals (23-24). However, Goossens et 
al. reported higher adipose tissue oxygen partial pressure in obese compared to lean 
individuals, accompanied by insulin resistance, impaired adipose tissue vascularization and 
higher adipose tissue gene expression of inflammatory cell markers (25). Hodson et al. did not 
find any evidence of hypoxia metabolic signatures (i.e. increased lactate, increased adipose 
glucose uptake) in obese individuals thus concluding that it is unlikely that adipose in obesity 
is hypoxic (26). Although there are methodological limitations on all of the above studies, 
we still need to bridge the gap of knowledge of what is considered the normal adipose partial 
oxygen pressure, a consensus of what is relative hypoxia in humans and whether is the driver 
of metabolic changes during adipose expansion.   
 
The relevance of HIF signalling could be considered in individuals with obstructive sleep apnea 
(OSA) which is highly associated with obesity and has been linked to impaired insulin 
sensitivity and higher risk of diabetes (27).  OSA is associated with repetitive episodes of 
hypoxia/reoxygenation (CIH) and has been associated with increased production of reactive 
oxygen species, fibrosis, and immune cell infiltration (28). Although OSA is a disorder 
manifested by repeated and transitory events of extremely variable oxygen desaturation and 
blood CO2 retention, it is clear that severe hypoxia (∼5% O2 inspired) per se decreases insulin 
sensitivity, whereas moderate hypoxia (13–15% O2) improves insulin sensitivity (29). 
Interestingly, CIH did not further increase serum proinflammatory cytokines or adipose tissue 
ER stress and hypoxia mRNA markers when compared with BMI-matched obesity without 
CIH (30). Individuals with OSA and different degrees of obesity or adiposity (normal, obese 
and morbidly obese) could provide the key information on molecular hypoxia signatures.   
 
Crucially, there is a need to refine methodology of measuring tissue oxygen availability and a 
consensus in defining adipose hypoxia in order to define in humans whether the HIF-pathway 
is switched on after a certain degree of adipose mass expansion, whether hypoxia develops 
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more in certain adipose depots (sub-cutaneous or visceral), whether is driven by a specific HIF-
a isoform and if this is an adaptive or a maladaptive response.    
 
Harnessing the HIF response by inhibiting the oxygen sensors. Programming for 
metabolic flexibility? 
Lessons from genetic models of PHD deletion 
One way of pre-empting and fine tuning the HIF response is by targeting the key HIF 
regulators, HIF-prolyl hydroxylases, that would permit stabilization of both HIF-1α and HIF-
2α.  Mouse models of either global or adipocyte-specific deletion of Phd2 (most abundant 
adipose isoform) showed beneficial metabolic outcomes. Recently, genetic deficiency of Phd2 
(hypomorphic for Phd2) in mice was shown to reduce body weight, white adipose tissue mass 
and subsequently WAT inflammation (31). These mice were protected from the development 
of age or diet-induced insulin resistance and had lower serum cholesterol levels and improved 
HDL/LDL ratios (31). Further experiments also revealed that Phd2 deficiency protected against 
steatohepatitis and atherosclerosis (32). The beneficial metabolic phenotype with reduced body 
weight, white fat mass, inflammation and protection from insulin resistance was confirmed in 
another study of adipose-specific deletion of Phd2 (33). Furthermore, specifically deleting 
Phd2 in adipocytes blunted lipolysis by mechanistically supressing the phosphorylation of 
hormone sensitive lipase, therefore reducing ectopic lipid deposition in liver or skeletal muscle 
(12). Supporting evidence towards beneficial metabolic outcomes also came from deletion of 
the Phd1 and Phd3 isoforms. Phd1 deficiency (Phd1–/–) improved glucose tolerance in DIO in 
mice, normalized hypercholesterolemia and reduced circulating inflammatory cells when 
crossed to LDLRKO mice (34). Acute loss of Phd3 (Phd3fl/fl injected with adenoviral Cre) in 
DIO decreased fasting blood glucose by 30% and fasting serum insulin by 50% compared 
to the diabetic controls (35). Mechanistically, the loss of Phd3 specifically stabilized HIF-
2α, which increased Irs2 transcription and insulin-stimulated Akt activation thus ameliorating 
the diabetic phenotype induced by DIO (35). Finally, deletion of another HIF regulator, 
asparaginyl hydroxylase (factor inhibiting HIF, or FIH), allowed HIF-α transactivation 
capacity (36). Fih–/– mice exhibited reduced body weight, elevated metabolic rate, and 
improved glucose and lipid homeostasis and were resistant to high-fat-diet-induced weight gain 
and hepatic steatosis (37). Taken together these data suggest that PHDs and FIH are essential 
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regulators of metabolism. Pharmacological targeting of these proteins may provide advantages 
during or after a hypoxic insult.   
 
Lessons from preclinical models: 
Is there a scope of activating the HIF signalling pathway to treat obesity and metabolic 
complications?  
HIF-prolyl hydroxylase inhibitors (PHDi) that target PHD1-2-3 are in phase II or III clinical 
trials for the treatment of renal anaemia. Apart from their role in increasing haemoglobin levels 
and correcting anaemia, preclinical studies have shown encouraging data that PHD inhibitors 
(i.e daprodustat and roxadustat) could lower serum cholesterol levels (38-39), possibly 
implicating them in novel pathways of regulating lipid homeostasis. In mouse preclinical 
models of diet-induced obesity or LDL-receptor deficient mice (LDLRKO), the HIF-prolyl 
hydroxylase inhibitor, FG-4497 (FibroGen Inc), reduced body weight, obesity-related adipose 
inflammation, insulin resistance and serum cholesterol levels (32). Additionally, in the 
LDLRKO mice FG-4497 reduced the atherosclerosis (32). Careful consideration should be 
given when designing strategies to activate the HIF pathway, for example to modulate whole 
body metabolism, as HIF activation targets a plethora of pathways and has been linked to 
cancer. However, taken together the beneficial effects of the HIF-prolyl hydroxylase inhibition  
on body weight regulation, glucose and lipid lowering, there is a strong case that this should 
be explored further as a potential therapeutic avenue to obesity-related complications such as 
diabetes and fatty liver (Figure 1). Further experiments to identify if targeting of a specific 
PHD isoform will shift towards the apparently metabolically beneficial effects of HIF-
2a activation might provide a way of minimizing complex responses from non-specificity.  
  
Conclusions  
In summary, the HIF transcriptional response is protective during states of cellular hypoxia. 
Harnessing the hypoxic response could have beneficial effects on metabolism and this is an 
increasingly important concept to be explored in the therapeutic settings of obesity-related 
metabolic dysfunction. Targeting the HIF/ hydroxylase pathway could offer therapeutic 
opportunities in for example regulating blood lipid levels. Further preclinical and experimental 
medicine studies are required to assess safe and effective treatment for human diseases 
associated with obesity such as dyslipeadimia and type 2 diabetes. 
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Figure 1. The balance of the HIF-a response in adipocytes determines metabolic 
outcomes.  
Adipose expansion in obesity leads to adipose hypoxia and HIF-1a activation. This  drives  pro-
inflammatory, fibrotic response but fails to induce vascularization thusleading to ectopic lipid 
accumulation and insulin resistance (right). In contrast, HIF-2a is essential in maintaining 
vascularization (left) during adipose expansion, facilitates the thermogenic response during 
cold exposure and has a beneficial metabolic outcome. HIF-prolyl hydroxylase deficiency or 
inhibition (PHDi), and thus stabilization of both isoforms is permissive towards a favourable 
metabolic profile (left).  
 
 
